Q-omics provides the consensus-scored FIZ1 profile across patient tissues and cancer cell-line models. FIZ1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FIZ1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FIZ1 RNA expression shows 19,278 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where FIZ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FIZ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FIZ1 survival associations across molecular data types. FIZ1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FIZ1 RNA expression–survival associations across cancer types. High FIZ1 expression shows unfavorable associations in MESO, ACC, LIHC and SKCM, but favorable associations in UVM and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for FIZ1 RNA expression.
This table summarizes FIZ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FIZ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FIZ1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, STAD, COAD and BRCA. The HNSC box plot shows higher FIZ1 RNA expression in tumor versus normal tissue (log2 FC = +0.408, t-test p < 0.001).
This table shows molecular features associated with FIZ1 in patient tissues and cancer cell lines. In patient samples, FIZ1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FIZ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
